FDA's New Rules: Checking if Pills Play Nice with Pregnancies
Published Date: 5/11/2026
Notice
Summary
The FDA just released final guidance to help drug makers study how their medicines affect pregnant women after approval. This update affects companies and researchers who must now follow clearer steps to check pregnancy safety, helping protect moms and babies. The guidance is effective immediately, with no new costs announced, but it encourages better, safer studies going forward.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
New Method Guidance: Registries & Rare Exposures
The final guidance updates methods for postapproval pregnancy safety work by clarifying the pregnancy registry section (including a new statistical methods subsection), broadening complementary study methods, expanding discussion on collecting data when rare exposures are expected, and updating terminology to include descriptive pregnancy safety studies. These methodological updates affect how sponsors and investigators design and document postapproval pregnancy safety investigations.
Final FDA Guidance for Pregnancy Safety Studies
On May 11, 2026 the FDA published a final guidance called "Postapproval Pregnancy Safety Studies" that gives recommendations to drug sponsors and investigators on how to design studies that assess safety outcomes in pregnant women after a drug or biologic is approved. The guidance finalizes a draft originally issued on May 9, 2019 and is available to industry and investigators for immediate use.
Guidance Is Non-Binding and Deregulatory
FDA states the guidance reflects its current thinking but is not binding; sponsors may use alternative approaches if they meet statute and regulation requirements. FDA also assessed this action as an Executive Order 14192 deregulatory action and the guidance contains no new collections of information under the Paperwork Reduction Act.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16714, Agency Information Collection Activities; Proposed Collection; Comment Request; Third Party Disclosure and Recordkeeping Requirements for Reportable Food
The Food and Drug Administration (FDA or the Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection provisions of FDA's third-party disclosure and recordkeeping requirements for reportable food.
2026-16712, Agency Information Collection Activities; Proposed Collection; Comment Request; Imports and Electronic Import Entries
The FDA wants your thoughts on how they collect info about imports and electronic import entries. If you’re involved in importing goods, this could affect you! They’re asking for comments by October 16, 2026, to help improve the process without adding extra costs or hassle.
2026-16715, Agency Information Collection Activities; Proposed Collection; Comment Request; Investigational New Drug Application Requirements
The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.
Previous / Next Documents
Previous: 2026-09267, Clostridioides Difficile Infection: Developing Drugs for Treatment, Reduction of Recurrence, or Prevention; Guidance for Industry; Availability
The FDA just released new guidance to help drug makers create medicines that treat, prevent, or stop Clostridioides difficile infections (CDI) from coming back. This update affects companies working on CDI drugs and aims to speed up safe, effective treatments reaching patients. The guidance is official as of May 11, 2026, and could save time and money by clarifying what’s needed for drug approval.
Next: 2026-09269, Pulmonary Tuberculosis: Developing Drugs for Treatment; Guidance for Industry; Availability
The FDA just released final guidance to help drug makers create new medicines to treat lung tuberculosis (TB). This update affects companies developing TB drugs by clarifying how to test and prove their treatments work safely and effectively. The guidance is official as of May 11, 2026, aiming to speed up better TB treatments without extra costs for the public.